Clinical Trial
doi: 10.1111/j.1525-1438.2003.13602.x.
Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5
Affiliations
- PMID: 14675308
- DOI: 10.1111/j.1525-1438.2003.13602.x
Item in Clipboard
Clinical Trial
Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5
Int J Gynecol Cancer.
2003 Nov-Dec.
Free article
Abstract
Mature results from GOG158 have clearly established carboplatin and paclitaxel as an effective and well tolerated standard regimen, providing a basis for the reference arm in GOG0182-ICON5, an ongoing multiarmed phase III trial of the Gynecologic Cancer InterGroup (GCIG) evaluating the incorporation of newer cytotoxic agents. Results from GOG158 will be reviewed, including an analysis of second-look surgical outcomes, followed by an update on the current status of GOG0182-ICON5.
Similar articles
-
Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5.Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:149-55. doi: 10.1111/j.1525-1438.2003.13362.x. Int J Gynecol Cancer. 2003. PMID: 14656272
-
Carboplatin versus cisplatin in ovarian cancer.Semin Oncol. 1995 Oct;22(5 Suppl 12):88-90. Semin Oncol. 1995. PMID: 7481869 Review.
-
Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.Semin Oncol. 2000 Jun;27(3 Suppl 7):3-7. Semin Oncol. 2000. PMID: 10952119 Review.
-
Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-44-S15-52. Semin Oncol. 1997. PMID: 9346222 Clinical Trial.
-
Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.Semin Oncol. 1997 Aug;24(4 Suppl 11):S11-28-S11-33. Semin Oncol. 1997. PMID: 9314296 Clinical Trial.
Cited by
-
Chemotherapy of ovarian cancer in elderly patients.Cancer Biol Med. 2015 Dec;12(4):292-301. doi: 10.7497/j.issn.2095-3941.2015.0077. Cancer Biol Med. 2015. PMID: 26779366 Free PMC article. Review.
-
Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.Cochrane Database Syst Rev. 2013 Oct 21;2013(10):CD010482. doi: 10.1002/14651858.CD010482.pub2. Cochrane Database Syst Rev. 2013. PMID: 24142521 Free PMC article.
-
Bilateral synchronous ovarian tumours: an uncommon case and review of the literature.Prz Menopauzalny. 2018 Jun;17(2):97-100. doi: 10.5114/pm.2018.77312. Epub 2018 Jun 30. Prz Menopauzalny. 2018. PMID: 30150919 Free PMC article.
-
Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer.BMC Med Genomics. 2008 Nov 28;1:59. doi: 10.1186/1755-8794-1-59. BMC Med Genomics. 2008. PMID: 19038057 Free PMC article.
-
Ovarian cancer survival by tumor dominance, a surrogate for site of origin.Cancer Causes Control. 2015 Apr;26(4):601-8. doi: 10.1007/s10552-015-0547-y. Epub 2015 Mar 13. Cancer Causes Control. 2015. PMID: 25771796 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
